. "Tetrathiomolybdate has demonstrated the ability to inhibit fibrosis in a number of well established animal models through the sequestration of available copper and inhibition of key fibrotric cytokines, including secreted protein acid rich in cysteine (SPARC), NFkappaB, TGF-beta, FGF-2, IL-1, IL-6, IL-8, and connective tissue growth factor (CTGF)."@en . . . . "ATN-224"@en . . . . . . "Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body."@en . . . . . . . "investigational"@en . . . "16330-92-0"@en . . " "@en . "Tetrathiomolybdate"@en . . "Investigated for use/treatment in liver disease and pulmonary fibrosis."@en . . . . . . . . . . . .